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e appreciate Dr. Erol’s (1) interest in our
article describing the phenotype of fat cell–
speciﬁc rictor knockout (FRic
2/2) mice (2).
Dr. Erol suggested that RBP4 may play a role
in the development of insulin resistance in FRic
2/2 mice.
RBP4 is an adipokine, whose elevated expression in,
and secretion from, adipocytes correlates with the de-
velopment of insulin resistance in various animal models
including the fat cell–speciﬁc GLUT4 knockout (G4A
2/2)
mice (3). Elevated circulating levels of RBP4 have also
been demonstrated in insulin-resistant obese subjects and
type 2 diabetic patients (4). Although a role for adipocyte-
RBP4 as a regulator of whole-body insulin sensitivity is
suggested, little is known about the regulation of the ex-
pression and secretion of RBP4 in adipocytes.
We agree that loss of adipocyte GLUT4 in G4A
2/2 mice
(3) and decreased GLUT4 expression in insulin-resistant
human subjects (3,4) are associated with an increase in
expression and secretion of RBP4. However, it is not
known whether the adipocyte-RBP4 response is caused by
the reduction in total GLUT4 levels or because of the
resulting decrease in insulin-stimulated glucose inﬂux. We
did not measure whether RBP4 was altered in FRic
2/2
mice. However, we do not think that RBP4 is the cause of
the systemic insulin resistance that was observed in FRic
2/2
mice. Insulin-stimulated glucose uptake is impaired in
FRic
2/2 adipocytes because of changes in insulin signaling
and defective GLUT4 translocation to the plasma mem-
brane in the absence of rictor (2). Total GLUT4 levels are not
changed in the FRic
2/2 adipocytes (2). The decrease in basal
glucose uptake in FRic
2/2 adipocytes (2) does not support
Dr. Erol’s model whereby decreased insulin-stimulated glu-
cose uptake induces increased basal glucose uptake. In
FRic
2/2 mice, loss of rictor expression does not only lead to
impaired GLUT4 translocation to the plasma membrane, but
multiple other defects (2). Most importantly, FRic
2/2 mice
show dysregulation of lipolysis and increased circulating
nonesteriﬁed fatty acid (2), a condition not observed in
G4A
2/2 mice (5). Because it is very well known that an
increase in circulating nonesteriﬁed fatty acid is sufﬁcient
to cause insulin resistance (6), this ﬁnding alone is suf-
ﬁcient to explain the insulin resistance observed in the
FRic
2/2 mice.
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